The CCR5 receptor antagonist maraviroc reduces viral load in patients with HIV-1 infection

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1522, 2006-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of HIV infection with the CCR5 antagonist maraviroc

By Kromdijk Wiete Huitema Alwin DR Mulder Jan Willem

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1215-1223

Informa Healthcare

Access to resources Recommend Favorite

Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection

By Caldwell David J Evans Jeffery D

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 18, 2008-12 ,pp. : 3231-3242

Informa Healthcare

Access to resources Recommend Favorite

Chemokine Receptor CCR5 Antagonist Maraviroc: Medicinal Chemistry and Clinical Applications

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 13, 2014-07 ,pp. : 1504-1514

Bentham Science Publishers

Access to resources Recommend Favorite

Maraviroc: A Review of its Use in the Management of CCR5-Tropic HIV-1 Infection

By Perry Caroline M.

Drugs, Vol. 70, Iss. 9, 2010-06 ,pp. : 1189-1213

Adis International

Access to resources Recommend Favorite

Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 13, 2008-09 ,pp. : 1140-1151

Bentham Science Publishers

Access to resources Recommend Favorite